Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,401–2,500 of 3,704
Jin, P., Ji, L., HUANG, Y., Ding, H., Xie, D., Jiang, X., Yuan, X., Cao, Z., Zhang, H., & Yuan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70849 · Cited by 1
Alali, M., Naveed, A. K., Alnounou, A., Alharami, M., & Nashed, B. (2026) · Cureus · doi:10.7759/cureus.109979 · Cited by 1
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Bruna-Mejías, A., Valenzuela‐Fuenzalida, J. J., Oyanedel-Amaro, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026) · Nutrients · doi:10.3390/nu18111781 · Cited by 3
Buchanan, A. M., VIRKUS, S., Fitzgerald, N. D., Hernandez, C. E., Habegger, K. M., Day, J., Hackett, T. A., Hardaway, J. A., & Galli, A. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00954 · Cited by 1
D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70894 · Cited by 1
Incretin therapies, nutrition and food insecurity in the UK
Spreckley, M., Ruggiero, C. F., & Brown, A. C. (2026) · Nature Medicine · doi:10.1038/s41591-026-04426-2 · Cited by 2
Incretin-based therapies: a new era in metabolic liver disease management
Elangovan, S., Cheah, C. C. M., & Goh, G. B. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.15 · Cited by 1
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma
Muller, H. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1768254 · Cited by 2
Piraccini, B. M., Vaño-Galvan, S., Blume‐Peytavi, U., Ribet, V., & Mengeaud, V. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01792-0 · Cited by 3
Vinciguerra, F., Stefano, C. D., Guccione, F., Degano, C., Nigro, S., Baratta, R., Piazza, L., Navarra, G., & Frittitta, L. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08754-7 · Cited by 2
Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025
Kildegaard, H., Andersen, J. H., Vinding, R., Kloppenborg, J. T., & Pottegård, A. (2026) · Obesity · doi:10.1002/oby.70234 · Cited by 1
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Davies, M. J., Aroda, V. R., Rosenstock, J., Capehorn, M., Pedersen, S. D., Morizzo, E., Sonali, M., Johansson, P. A., Grice, D., Andersson, A., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00748-8 · Cited by 3
Kakkar, A. K., Payra, S., & Charaya, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70952 · Cited by 1
Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro)
Bhandari, P., Ray, A., Bhatt, P. R., Sapkota, S., Pande, S. K., Mustarin, S., Guragai, N., & Aziz, K. (2026) · Cureus · doi:10.7759/cureus.110692 · Cited by 1
Node, K., Batterham, R. L., Liu‐Seifert, H., Li, R., Yoshino, M., Oura, T., Tanizawa, Y., & Komuro, I. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2686052 · Cited by 1
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists
Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1
Basolo, A., Piaggi, P., Angeli, V., Fierabracci, P., Bologna, C., Paolucci, G., Salvetti, G., Chiovato, L., Krakoff, J. A., Landi, A., et al. (2026) · Obesity · doi:10.1002/oby.70236 · Cited by 1
The years-of-life advantage of metabolic and bariatric surgery in advanced kidney disease
Kindel, T. L., & Northup, C. J. (2026) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2026.117102 · Cited by 1
Sarić, M. M., Šikić, N. L., Sorić, T., Sarić, A., Ivanišin, A., Brodić, I., & Milić, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125495 · Cited by 2
Busk‐Cirera, L., Carlsen, I. Ø., Madsen, L. B., Sandsdal, R. M., Jensen, E., Jensen, S. B. K., & Torekov, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71006 · Cited by 6
Overgaard, R. V., Agersø, H., Hollensen, C., Rathor, N., & Bomberg, E. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71030 · Cited by 1
Varma, G., Murugadoss, K., Kurian, M. E., Varghese, J., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag035 · Cited by 3
Kokkinos, A. D., Thethi, T. K., Lee, C. J., Neff, L. M., Stefański, A., Cao, D., Rodríguez, Á., & Bartee, A. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71009 · Cited by 4
Self-citationStructurally defining neurokinin selectivity to improve NK2R agonists
Pavlovskyi, A., Ren, Y., Gestal-Mato, M., Olsen, O. H., Schwartz, T. W., Gerhart‐Hines, Z., & Liu, X. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01820-9 · Cited by 1
Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery
Brown, A., Patel, S. S., Kozato, A., Orandi, B. J., Massie, A. M., Vu, A. H., Somoza, E., Mei, T., Desai, S., Zhang, D. S., et al. (2026) · Obesity · doi:10.1002/oby.70246 · Cited by 8
Emara, A., Emara, M., Mansour, A., Elkholy, M., Abbas, O., Abdul‐Hafez, H. A., Azzawi, M. A. D. A., & Shubietah, A. R. M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02218-9 · Cited by 1
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
Kahkedjian, F., Shah, J., & Kreidieh, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1885961 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
Tirzepatide‐Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report
Shimada, T., Nose, Y., Tojima, H., Maehata, T., & Kato, A. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73085 · Cited by 3
The gendered “stathetic” body: a scientifically informed philosophical approach to corporality
Córdoba, M., Labombarda, F., Dupré, J., Martínez, A. B., & Negretti-Borga, D. M. (2026) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-026-00743-4 · Cited by 1
Bidesie, J. R., & Oudman, E. (2026) · Obesity · doi:10.1002/oby.70256 · Cited by 1
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Corso, H., Graybeal, A. J., Hoelscher, E., Roberson, S., Curran, B., Johnson, C., & Johnson, K. E. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1834580 · Cited by 3
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145358 · Cited by 6
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Alsaleh, N. A., Seif‐Eldein, N. A., Malky, A. M. E., Al-Hashem, H., & Idriss, H. K. (2026) · World Journal of Surgery · doi:10.1002/wjs.70487 · Cited by 1
Abdallah, H., Khalil, M., Mahdi, L., Pietragalla, G., Faienza, M. F., Garruti, G., & Portincasa, P. (2026) · Nutrients · doi:10.3390/nu18142317 · Cited by 1
Bosy‐Westphal, A., Enderle, J., Norman, K., & Müller, M. J. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70334 · Cited by 2
GLP ‐1‐Based Therapy for Obstructive Sleep Apnoea
Zheng, Y., & Yee, B. J. (2026) · Respirology · doi:10.1002/resp.70282 · Cited by 1
Body Contouring Surgery in the Era of GLP–1 Receptor Agonists: A Narrative Review
Duque, M. A. S., & Galvis, A. E. G. (2026) · Indian Journal of Plastic Surgery · doi:10.1055/s-0046-1824526 · Cited by 1
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand
DiStefano, M. J., Tilley, A., Paratane, D., Gyamfi, H. G., Moore, G. D., & Nair, K. V. (2026) · JAMA Health Forum · doi:10.1001/jamahealthforum.2026.2207 · Cited by 3
Scott, I. C., Smith, T. M., Babatunde, O. O., Barker, C., Battista, S., Beesley, R., Beesley, R. P., Birkinshaw, H., Brooke, M., Chaplin, H., et al. (2026) · Rheumatology · doi:10.1093/rheumatology/keag320 · Cited by 2
Quan, A. T., Nguyen, H. L., & Tran, M. T. N. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103466 · Cited by 1
Sadiq, H., Amini, Z., Husain, M. M., Alao, D. O., & Jaiganesh, T. (2026) · Cureus · doi:10.7759/cureus.113368 · Cited by 1
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
Adiposology: A Tissue-centric Clinical Framework for Cardiometabolic Risk Beyond Body Mass Index
BHATTACHARYYA, S., Sen, S., & Anthuvan, T. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_3_26 · Cited by 1
Montenegro-Chanalata, M. B., & Guamán-Arcos, A. J. (2025) · INNOVATE Research Journal · doi:10.65133/irj.v1.n1.2025/a10 · Cited by 1
Al-Rashid, A. H., & Ali, F. (2026) · Cureus · doi:10.7759/cureus.113910 · Cited by 1
Amylin: A Multi‐Functional Pancreatic Hormone—A Review
Foll, C. L., & Lutz, T. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71146 · Cited by 1
Ruga, S., Matarese, E., Bava, R., Lombardi, C., Dimatteo, T., Miscio, L., Raponi, M., Giordano, A., Sansone, C., Liguori, G., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19081230 · Cited by 1
Increasing skeletal muscle mass and strength during incretin-based weight loss
Mendias, C. L., & Awan, T. M. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100317 · Cited by 1
Glucose-responsive probiotics for glycaemic modulation in mice and monkeys
Guan, N., Kong, D., Gao, X., Niu, L., Zhou, Y., Yu, G., Gao, T., Liu, M., Ma, W., Jin, Y., et al. (2026) · Nature · doi:10.1038/s41586-026-10909-6 · Cited by 4
mRNA-LNP therapeutics for obesity: weight loss with metabolic repair
Liao, J., Farbiak, L., Siegwart, D. J., & Chuang, L. I. U. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01297-y · Cited by 9
Menezes, M. L. L., Chiappa, M. E. G., Fuentes-Kloss, R., Tuesta, M., Santos, P., Filho, A. S. S., & Chiappa, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71220 · Cited by 1
Tirzepatide non-response with subsequent semaglutide response in class 2 obesity
Vignera, S. L., & Condorelli, R. A. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag245 · Cited by 3
Green, D., & Glynn, N. (2026) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-26-0059 · Cited by 1
Vergallo, R., & Liuzzo, G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac388 · Cited by 1
Integrated Care Model of Adiposity-Related Chronic Diseases
Jemtel, T. H. L., Samson, R., & Oparil, S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01223-3 · Cited by 1
Selección de lo mejor del año en 2022 en riesgo vascular y rehabilitación cardiaca
Olmo, M. R. F., Fort, A. C., Llergo, J. T., Martín, D. M., Alonso, M. B., Quesada, M. M., Palau, P., & Ruíz, R. C. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2022.10.002 · Cited by 1
Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
Wong, E. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.10.003 · Cited by 1
¿Podrán los nuevos fármacos frenar la epidemia mundial de la obesidad y el sobrepeso?
Guillem, F. C. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102518 · Cited by 2
Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed?
Malkani, N. P., & Aroda, V. R. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000787 · Cited by 2
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Talha, K. M., Fonarow, G. C., Virani, S. S., & Butler, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1155 · Cited by 1
Brave New World: Improving Obesity and Preventing Cardiovascular Disease
O’Keefe, J. H., O’Keefe, E. L., Nassif, M. E., & Lavie, C. J. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.11.012 · Cited by 1
Mazaheri, T., Ansari, S., Nallagonda, M., Kollmann, L., Nickel, F., Seyfried, F., & Miras, A. D. (2023) · Die Chirurgie · doi:10.1007/s00104-023-01830-z · Cited by 3
STACHYRA, B., WOLANIN, M., STAWIKOWSKI, C., ZIELONKA, B., Osińska, A., WOLANIN, I., MADEJ, K., Dengler, B., KOWALCZYK, I., & KRAWIEC, P. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.18.01.003 · Cited by 2
Prädiabetes als therapeutische Herausforderung in der Inneren Medizin
Kantartzis, K., Fritsche, A., & Birkenfeld, A. L. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01546-6 · Cited by 5
Diabetes in the Pediatric Age Group: A Case Series and Review of Literature
Valenzuela-Ruiz, J. R., Bobadilla-Olaje, G. F., Calleja-López, J. R. T., Ruibal-Tavares, E., Rivera-Rosas, C. N., Aguilera-Duarte, L. J., & Ruiz-Quiroz, J. O. (2023) · Journal of Pediatrics Review · doi:10.32598/jpr.11.2.1101.1 · Cited by 1
Lira, F. K. A., Farias, B. S. G. H., Costa, Á. M. O., et al. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n5-092 · Cited by 1
Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug
Prosecký, R., & Vítovec, J. (2023) · Klinická farmakologie a farmacie · doi:10.36290/far.2023.012 · Cited by 2
Body Mass Index, Obesity, and Mortality—Part II: Weight Loss and Weight Cycling
Sanders, L., Mestre, L. M., Ejima, K., Mehta, T. S., Keith, S. W., Maki, K. C., & Allison, D. B. (2023) · Nutrition Today · doi:10.1097/nt.0000000000000615 · Cited by 1
Revisão da literatura sobre as principais drogas vigentes para tratamento da obesidade no Brasil
PIZZOL, M. H., Gerônimo, R. M. P., Pereira, G. L., Rodrigues, A. G., AMARAL, F. H. F. D., Neto, C. M. G., Oliveira, T. M. D., CECCON, R., Silva, S. O., Guimarães, B. B. S., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n4-153 · Cited by 5
Diagnosis and treatment of prediabetes as prevention of type 2 diabetes: A review
Petunina, N. A., Martirosian, N. S., Викторович, Х. М., Zhutaeva, M. A., Shaposhnikova, A. A., Karpenko, E. V., & Abdulganieva, Z. A. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.4.202312 · Cited by 5
Is Metabolic Surgery Having an Identity Crisis?
COHEN, R. V., Lingay, I., le Roux, C. W., & Sumithran, P. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06786-x · Cited by 1
Obesity, Metabolic Syndrome, and Sleep Disorders
Duan, D., & Jun, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_53-1 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Kurt, B., & Kahles, F. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01109-1 · Cited by 1
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_9 · Cited by 1
Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual
Olmo, M. R. F., & Llergo, J. T. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00011-0 · Cited by 2
Intersections between HIV and obesity in emerging economies
Levi, J., Fairhead, C., & Hill, A. M. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000827 · Cited by 1
Sarma, S., Tran, S., & Fralick, M. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230820 · Cited by 1
Tratamento da obesidade com análogos de GLP-1: uma revisão de literatura
Ardais, G. D., de Lima, N. F., & Batista, S. L. (2023) · Revista Interdisciplinar de Saúde e Educação · doi:10.56344/2675-4827.v4n3a2023.30 · Cited by 1
McCarthy, W. J., & Ferguson, F. (2023) · The Journal of Physiology · doi:10.1113/jp285880 · Cited by 1
Obésité sarcopénique : des étapes décisives et des perspectives prometteuses
Boirie, Y., Guillet, C., Pouget, M., Walrand, S., & Pinel, A. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/s0985-0562(24)00009-8 · Cited by 1
Chianelli, M., Albanese, A., Carabotti, M., Casarotto, D., Pergola, G. D., Disoteo, O., Grandone, I., Medea, G., Nisoli, E., Raffaelli, M., et al. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01417-8 · Cited by 3
Liuzzo, G., & Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae076 · Cited by 1
Prediabetes: difícil decisión en el tratamiento farmacológico
Martinez, C. A. G., Corredor-Rengifo, D., & Abreu-Lomba, A. (2024) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.1.10267
Adipositastherapie in Deutschland – quo vadis?
Hauner, H. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2240-9125 · Cited by 1
Tirzepatid - der Gamechanger in der Diabetestherapie?
Negrean, M. (2024) · Info Diabetologie · doi:10.1007/s15034-023-4901-y · Cited by 1
Pharmakotherapie der Adipositas
Roser, P. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01167-z · Cited by 1
Freinkel, K. O. U., Yehoshua, I., Cohen, B., Peleg, R., & Adler, L. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02324-5 · Cited by 1
Guidelines for obesity clinic consultations in primary healthcare clinics
Kang, J., & Kim, K. K. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.4.240 · Cited by 3
Clinical progress note: Glucagon‐like peptide‐1 receptor agonists and hospitalized patients
Ravee, A., Burroughs‐Ray, D., Jackson, C., Spratt, S. E., & Sata, S. S. (2024) · Journal of Hospital Medicine · doi:10.1002/jhm.13357 · Cited by 1
A data-driven approach to improve wellness and reduce recurrence in cancer survivors
Hariharan, R., Hood, L., & Price, N. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1397008 · Cited by 4
Pharmacological treatments for adults with overweight and obesity without diabetes
Shang, W., Xu, H., Li, M., Ren, J., Huang, X., Li, J., Wang, X., Wang, Q., Ma, Y., Madrid, E., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015861 · Cited by 7
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.